Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 12
Submit an article Journal homepage
48
Views
26
CrossRef citations to date
0
Altmetric
Research Article

Immunological Effects of Interferon-alpha on Chronic Myelogenous Leukemia

Fabiola Attié de Castro School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Sao Paulo, Brazil
,
Patricia Vianna Bonini Palma Regional Blood Centre of Ribeirão Preto, Sao Paulo, Brazil
,
Fabiana Rossetto Morais Regional Blood Centre of Ribeirão Preto, Sao Paulo, Brazil
,
Belinda Pinto Simões Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Sao Paulo, Brazil
,
Paulo Villas-Boas Carvalho Regional Blood Centre of Ribeirão Preto, Sao Paulo, Brazil
,
Sebastião José Ismael Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Sao Paulo, Brazil
,
Carmen Passos Voltarelli Department of Clinical Medicine, School of Medicine of Campinas, University of São Paulo, Sao Paulo, Brazil
&
Júlio César Morais Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Sao Paulo, Brazil
 show all
Pages 2061-2067 | Published online: 05 Aug 2011

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mette Ilander, Perttu Koskenvesa, Sari Hernesniemi, Thomas Lion, Kimmo Porkka & Satu Mustjoki. (2014) Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy. Leukemia & Lymphoma 55:4, pages 934-937.
Read now
Vibe Skov, Caroline Hasselbalch Riley, Mads Thomassen, Thomas Stauffer Larsen, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse & Hans Carl Hasselbalch. (2013) Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leukemia & Lymphoma 54:10, pages 2269-2273.
Read now

Articles from other publishers (24)

Inge G.P. Geelen, Stein-Erik Gullaksen, Mette M. Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M.A. Blijlevens, Willem M. Smit, Bjorn T. Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M.A. Koppes, Peter E. Westerweel, Henrik Hjorth-Hansen & Jeroen J.W.M. Janssen. (2023) Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of Hematology 102:6, pages 1395-1408.
Crossref
Maria Estefania VianoNatalia Soledad BaezConstanza Savid-FronteraNicolás Leonel LidonDeborah L. HodgeAndré HerbelinJean-Marc GombertAlice BarbarinMaria Cecilia Rodriguez-Galan. (2022) Virtual Memory CD8 + T Cells: Origin and Beyond . Journal of Interferon & Cytokine Research 42:12, pages 624-642.
Crossref
Jonathan A. Webster, Tara M. Robinson, Amanda L. Blackford, Erica Warlick, Anna Ferguson, Ivan Borrello, Marianna Zahurak, Richard J. Jones & B. Douglas Smith. (2021) A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia Research 111, pages 106737.
Crossref
Erin Naismith, Janine Steichen, Sieghart Sopper & Dominik Wolf. (2021) NK Cells in Myeloproliferative Neoplasms (MPN). Cancers 13:17, pages 4400.
Crossref
Hui Mu, Xiaojian Zhu, Hui Jia, Lu Zhou & Hong Liu. (2021) Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. Frontiers in Oncology 11.
Crossref
SVETLANA BUNIMOVICH-MENDRAZITSKY & LEONID SHAIKHET. (2021) STABILITY ANALYSIS OF A MATHEMATICAL MODEL FOR CHRONIC MYELOID LEUKEMIA ERADICATION. Journal of Biological Systems 29:01, pages 169-191.
Crossref
Fabien Muselli, Jean-François Peyron & Didier Mary. (2019) Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia. International Journal of Molecular Sciences 20:22, pages 5616.
Crossref
Svetlana Bunimovich‐Mendrazitsky, Natalie Kronik & Vladimir Vainstein. (2018) Optimization of Interferon–Alpha and Imatinib Combination Therapy for Chronic Myeloid Leukemia: A Modeling Approach. Advanced Theory and Simulations 2:1, pages 1800081.
Crossref
Tatsuro Jo, Kazuhiro Noguchi, Shizuka Hayashi, Sadaharu Irie, Risa Hayase, Haruna Shioya, Youhei Kaneko, Kensuke Horio & Jun Taguchi. (2017) Long‑lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib. Oncology Letters.
Crossref
Emilie Cayssials & Francois Guilhot. (2017) Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches. BioDrugs 31:3, pages 143-149.
Crossref
Amy Hughes & Agnes S. M. Yong. (2017) Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Frontiers in Immunology 8.
Crossref
Vaclava Polivkova, Peter Rohon, Hana Klamova, Olga Cerna, Martina Divoka, Nikola Curik, Jan Zach, Martin Novak, Iuri Marinov, Simona Soverini, Edgar Faber & Katerina Machova Polakova. (2016) Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLOS ONE 11:5, pages e0155959.
Crossref
Mette Ilander, Can Hekim & Satu Mustjoki. (2014) Immunology and Immunotherapy of Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 9:1, pages 17-23.
Crossref
Mette Ilander, Anna Kreutzman, Peter Rohon, Teresa Melo, Edgar Faber, Kimmo Porkka, Jukka Vakkila & Satu Mustjoki. (2014) Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy. PLoS ONE 9:1, pages e87794.
Crossref
Amedeo Amedei, Marisa Benagiano, Chiara della Bella, Elena Niccolai & Mario M. D'Elios. (2011) Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology 2011, pages 1-17.
Crossref
Norberto W. Zwirner & Carolina I. Domaica. (2010) Cytokine regulation of natural killer cell effector functions. BioFactors 36:4, pages 274-288.
Crossref
Valentina Nardi, Olaia Naveiras, Mohammad Azam & George Q. Daley. (2009) ICSBP-mediated immune protection against BCR-ABL–induced leukemia requires the CCL6 and CCL9 chemokines. Blood 113:16, pages 3813-3820.
Crossref
Magali Terme, Evelyn Ullrich, Nicolas F Delahaye, Nathalie Chaput & Laurence Zitvogel. (2008) Natural killer cell–directed therapies: moving from unexpected results to successful strategies. Nature Immunology 9:5, pages 486-494.
Crossref
Jieru Meng, Zhen Yan, Yongjie Wu, Mingtang Gao, Wenguang Li, Fei Gao, Hongxing Wang, Wei Han & Yingqi Zhang. (2008) Preclinical safety evaluation of IFNα2a-NGR. Regulatory Toxicology and Pharmacology 50:3, pages 294-302.
Crossref
Lisa A. Kujawski & Moshe Talpaz. (2007) The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine & Growth Factor Reviews 18:5-6, pages 459-471.
Crossref
Reuben Benjamin, Asim Khwaja, Nalini Singh, Jenny McIntosh, Anthony Meager, Meenu Wadhwa, Christian Streck, Catherine Ng, Andrew M. Davidoff & Amit C. Nathwani. (2006) Continuous delivery of human type I interferons (α/β) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood 109:3, pages 1244-1247.
Crossref
Stergios J. Moschos & John M. Kirkwood. 2007. General Principles of Tumor Immunotherapy. General Principles of Tumor Immunotherapy 405 430 .
E Brin, I Atencio, B K Helmich, D Maneval & D LaFace. (2006) Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma. Cancer Gene Therapy 13:7, pages 664-675.
Crossref
M. Copland, A. R. Fraser, S. J. Harrison & T. L. Holyoake. (2004) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunology, Immunotherapy 54:4, pages 297-306.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.